Fate Therapeutics Inc.
1.25
-0.04 (-3.10%)
At close: Jan 14, 2025, 3:59 PM
1.27
1.20%
Pre-market Jan 15, 2025, 04:03 AM EST
undefined%
Bid 1.26
Market Cap 142.94M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.64
PE Ratio (ttm) -0.77
Forward PE n/a
Analyst Hold
Ask 1.28
Volume 4,192,838
Avg. Volume (20D) 3,151,672
Open 1.31
Previous Close 1.29
Day's Range 1.04 - 1.31
52-Week Range 1.04 - 8.83
Beta undefined

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2013
Employees 181
Stock Exchange NASDAQ
Ticker Symbol FATE

Analyst Forecast

According to 10 analyst ratings, the average rating for FATE stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 378.09% from the latest price.

Buy 30.00%
Hold 50.00%
Sell 10.00%
Stock Forecasts

Next Earnings Release

Fate Therapeutics Inc. is scheduled to release its earnings on Feb 24, 2025, during market hours.
Analysts project revenue of $1.12M, reflecting a -33.17% YoY shrinking and earnings per share of -0.44, making a -2.22% decrease YoY.
1 month ago · Source
+2.64%
Fate Therapeutics shares are trading higher after ... Unlock content with Pro Subscription
1 month ago · Source
+12.38%
Fate Therapeutics shares are trading higher after the company presented 6-month follow-up data on the first patient treated in its Phase 1 Autoimmunity study.